The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova

• Published in: Nature communications Vol. 15; no. 1; pp. 2962 - 9
• Main Authors: Chitwood, Melanie H., Colijn, Caroline, Yang, Chongguang, Crudu, Valeriu, Ciobanu, Nelly, Codreanu, Alexandru, Kim, Jaehee, Rancu, Isabel, Rhee, Kyu, Cohen, Ted, Sobkowiak, Benjamin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.04.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 45/23; 631/114/739; 692/308/174; 692/699/255/1856; Fitness; Gene sequencing; Genomes; Humanities and Social Sciences; multidisciplinary; Multidrug resistance; Mutation; Mycobacterium tuberculosis; Reproductive fitness; Science; Science (multidisciplinary); Tuberculosis; Beijing China; China; Moldova
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-47282-9

The projected trajectory of multidrug resistant tuberculosis (MDR-TB) epidemics depends on the reproductive fitness of circulating strains of MDR M. tuberculosis (Mtb) . Previous efforts to characterize the fitness of MDR Mtb have found that Mtb strains of the Beijing sublineage (Lineage 2.2.1) may be more prone to develop resistance and retain fitness in the presence of resistance-conferring mutations than other lineages. Using Mtb genome sequences from all culture-positive cases collected over two years in Moldova, we estimate the fitness of Ural (Lineage 4.2) and Beijing strains, the two lineages in which MDR is concentrated in the country. We estimate that the fitness of MDR Ural strains substantially exceeds that of other susceptible and MDR strains, and we identify several mutations specific to these MDR Ural strains. Our findings suggest that MDR Ural Mtb has been transmitting efficiently in Moldova and poses a substantial risk of spreading further in the region. Chitwood et al. report on the rapid expansion of a Ural-lineage multidrug resistant strain of Mycobacterium tuberculosis in Moldova. This strain has an estimated reproduction number more than two times greater than otherwise similar drug susceptible strains.